Vincent Bekker1, Merijn W Bijlsma2, Diederik van de Beek2, Taco W Kuijpers1, Arie van der Ende3. 1. Emma Children's Hospital, Academic Medical Center, Center for Infection and Immunity Amsterdam, Amsterdam, Netherlands. 2. Department of Neurology, Academic Medical Center, Center for Infection and Immunity Amsterdam, Amsterdam, Netherlands. 3. Department of Medical Microbiology, Academic Medical Center, Center for Infection and Immunity Amsterdam, Amsterdam, Netherlands; Netherlands Reference Laboratory for Bacterial Meningitis, Amsterdam, Netherlands. Electronic address: a.vanderende@amc.uva.nl.
Abstract
BACKGROUND: Group B streptococcus is the most common cause of neonatal infections. We studied the clinical and molecular epidemiology of invasive group B streptococcus infection in children younger than 3 months in the Netherlands over 25 years. We assessed the effect of the Dutch guidelines, introduced in 1999, for prevention of group B streptococcus, consisting of intravenous antibiotic prophylaxis during labour in cases of premature labour, prolonged rupture of membranes, or fever during delivery. METHODS: We did this nationwide surveillance study with data from 1987 to 2011, from the Netherlands Reference Laboratory for Bacterial Meningitis. We included data for patients aged 3 months or younger with positive blood culture or cerebrospinal fluid culture for group B streptococcus and Escherichia coli infection. Early onset was defined as less than 7 days after birth and late onset was defined as 7 or more days after birth. We did multilocus sequence typing of a random subset of group B streptococcus samples to assess changes in sequence type (Mann-Kendall trend test) and the distribution of clonal complexes (χ(2) and Fisher exact test) before the introduction of prevention guidelines (1987-99) and afterwards (2000-11). We compared incidences and the distribution of clonal complexes before and after the introduction of guidelines. FINDINGS: Most cases of group B streptococcus had early onset (696/1075; 65%). The incidence of invasive group B streptococcus infection increased from 0·20 per 1000 livebirths in 1987, to 0·32 per 1000 livebirths in 2011 (p<0·0001). The incidence of early-onset disease increased from 0·11 per 1000 livebirths to 0·19 per 1000 livebirths (p<0·0001). The incidence of invasive Escherichia coli infection was 0·05 in 1987, and 0·16 in 2011 (p=0·17). Early-onset group B streptococcus infection caused by isolates belonging to clonal complex 17 was more common in the post-implementation period than in the pre-implementation period (p=0·002). INTERPRETATION: The introduction of prevention guidelines for invasive group B streptococcus disease in 1999 did not reduce the incidence of disease in neonates. The guidelines should be reassessed and alternative approaches to prevent infant invasive group B streptococcus disease should be sought. FUNDING: National Institute of Public Health and the Environment, the European Union's seventh framework programme, Netherlands Organization for Health Research and Development, Academic Medical Center, and the European Research Council.
BACKGROUND:Group B streptococcus is the most common cause of neonatal infections. We studied the clinical and molecular epidemiology of invasive group B streptococcus infection in children younger than 3 months in the Netherlands over 25 years. We assessed the effect of the Dutch guidelines, introduced in 1999, for prevention of group B streptococcus, consisting of intravenous antibiotic prophylaxis during labour in cases of premature labour, prolonged rupture of membranes, or fever during delivery. METHODS: We did this nationwide surveillance study with data from 1987 to 2011, from the Netherlands Reference Laboratory for Bacterial Meningitis. We included data for patients aged 3 months or younger with positive blood culture or cerebrospinal fluid culture for group B streptococcus and Escherichia coli infection. Early onset was defined as less than 7 days after birth and late onset was defined as 7 or more days after birth. We did multilocus sequence typing of a random subset of group B streptococcus samples to assess changes in sequence type (Mann-Kendall trend test) and the distribution of clonal complexes (χ(2) and Fisher exact test) before the introduction of prevention guidelines (1987-99) and afterwards (2000-11). We compared incidences and the distribution of clonal complexes before and after the introduction of guidelines. FINDINGS: Most cases of group B streptococcus had early onset (696/1075; 65%). The incidence of invasive group B streptococcus infection increased from 0·20 per 1000 livebirths in 1987, to 0·32 per 1000 livebirths in 2011 (p<0·0001). The incidence of early-onset disease increased from 0·11 per 1000 livebirths to 0·19 per 1000 livebirths (p<0·0001). The incidence of invasive Escherichia coli infection was 0·05 in 1987, and 0·16 in 2011 (p=0·17). Early-onset group B streptococcus infection caused by isolates belonging to clonal complex 17 was more common in the post-implementation period than in the pre-implementation period (p=0·002). INTERPRETATION: The introduction of prevention guidelines for invasive group B streptococcus disease in 1999 did not reduce the incidence of disease in neonates. The guidelines should be reassessed and alternative approaches to prevent infant invasive group B streptococcus disease should be sought. FUNDING: National Institute of Public Health and the Environment, the European Union's seventh framework programme, Netherlands Organization for Health Research and Development, Academic Medical Center, and the European Research Council.
Authors: Christopher Whidbey; Kellie Burnside; Raquel M Martinez; Claire Gendrin; Jay Vornhagen; Andrew Frando; Maria Isabel Harrell; Ryan McAdams; Lakshmi Rajagopal Journal: Clin Res Infect Dis Date: 2015-09-03
Authors: Clara Carreras-Abad; Madeleine Cochet; Tom Hall; Laxmee Ramkhelawon; Asma Khalil; Elisabeth Peregrine; Latha Vinayakarao; Sharmila Sivarajan; Rosol Hamid; Tim Planche; Elizabeth Sheridan; Stephen Winchester; Jane Plumb; Abdelmajid Djennad; Nick Andrews; Kirsty Le Doare; Paul Heath Journal: Health Technol Assess Date: 2019-12 Impact factor: 4.014
Authors: Srinivas Acharya Nanduri; Susan Petit; Chad Smelser; Mirasol Apostol; Nisha B Alden; Lee H Harrison; Ruth Lynfield; Paula S Vagnone; Kari Burzlaff; Nancy L Spina; Elizabeth M Dufort; William Schaffner; Ann R Thomas; Monica M Farley; Jennifer H Jain; Tracy Pondo; Lesley McGee; Bernard W Beall; Stephanie J Schrag Journal: JAMA Pediatr Date: 2019-03-01 Impact factor: 16.193
Authors: Helgi Padari; Tuuli Metsvaht; Eva Germovsek; Charlotte I Barker; Karin Kipper; Koit Herodes; Joseph F Standing; Kersti Oselin; Tõnis Tasa; Hiie Soeorg; Irja Lutsar Journal: Antimicrob Agents Chemother Date: 2018-04-26 Impact factor: 5.191
Authors: Anna C Seale; Angela C Koech; Anna E Sheppard; Hellen C Barsosio; Joyce Langat; Emily Anyango; Stella Mwakio; Salim Mwarumba; Susan C Morpeth; Kirimi Anampiu; Alison Vaughan; Adam Giess; Polycarp Mogeni; Leahbell Walusuna; Hope Mwangudzah; Doris Mwanzui; Mariam Salim; Bryn Kemp; Caroline Jones; Neema Mturi; Benjamin Tsofa; Edward Mumbo; David Mulewa; Victor Bandika; Musimbi Soita; Maureen Owiti; Norris Onzere; A Sarah Walker; Stephanie J Schrag; Stephen H Kennedy; Greg Fegan; Derrick W Crook; James A Berkley Journal: Nat Microbiol Date: 2016-05-23 Impact factor: 17.745
Authors: Yanli Liu; Minli Zhu; Xiaoqin Fu; Jiaojiao Cai; Shangqin Chen; Yuanyuan Lin; Na Jiang; Si Chen; Zhenlang Lin Journal: Int J Gen Med Date: 2021-06-29
Authors: Mirjam Freudenhammer; Konstantinos Karampatsas; Kirsty Le Doare; Fabian Lander; Jakob Armann; Daniel Acero Moreno; Margaret Boyle; Horst Buxmann; Ruth Campbell; Victoria Chalker; Robert Cunney; Lorraine Doherty; Eleri Davies; Androulla Efstratiou; Roland Elling; Matthias Endmann; Jochen Essers; Roland Hentschel; Christine E Jones; Steffen Kallsen; Georgia Kapatai; Marcus Krüger; Shamez Ladhani; Theresa Lamagni; Diane Lindsay; Mary Meehan; Catherine P O'Sullivan; Darshana Patel; Arlene J Reynolds; Claudia Roll; Sven Schulzke; Andrew Smith; Anja Stein; Axel von der Wense; Egbert Voss; Christian Wieg; Christoph Härtel; Paul T Heath; Philipp Henneke Journal: Front Immunol Date: 2021-06-02 Impact factor: 7.561